

LOVASTATIN

Page: 1

Compilation date: 15/04/2016

Revision No: 1

Section 1: Identification of the substance/mixture and of the company/undertaking

1.1. Product identifier

Product name: LOVASTATIN

CAS number: 75330-75-5

Product code: BIL1008

Synonyms: MEVINOLIN

6-ALPHA-METHYLCOMPACTIN

1.2. Relevant identified uses of the substance or mixture and uses advised against

1.3. Details of the supplier of the safety data sheet

Company name: Apollo Scientific Ltd

Units 3 & 4
Parkway
Denton
Manchester
M34 3SG

UK

Tel: 0161 337 9971 **Fax:** 0161 336 6932

Email: david.tideswell@apolloscientific.co.uk

1.4. Emergency telephone number

Section 2: Hazards identification

2.1. Classification of the substance or mixture

Classification under CLP: Acute Tox. 4: H302; Repr. 2: H361d

Most important adverse effects: Harmful if swallowed. Suspected of damaging the unborn child.

2.2. Label elements

Label elements:

Hazard statements: H302: Harmful if swallowed.

H361d: Suspected of damaging the unborn child.

Signal words: Warning

Hazard pictograms: GHS07: Exclamation mark

GHS08: Health hazard





LOVASTATIN

Page: 2

Precautionary statements: P308+313: IF exposed or concerned: Get medical advice/attention.

P261: Avoid breathing dust.

P280: Wear protective gloves/protective clothing/eye protection/face protection.

2.3. Other hazards

PBT: This product is not identified as a PBT/vPvB substance.

Section 3: Composition/information on ingredients

3.1. Substances

Chemical identity: LOVASTATIN

CAS number: 75330-75-5

Section 4: First aid measures

4.1. Description of first aid measures

Skin contact: Wash immediately with plenty of soap and water.Eye contact: Bathe the eye with running water for 15 minutes.

Ingestion: Wash out mouth with water. Do not induce vomiting. If conscious, give half a litre of water

to drink immediately. Transfer to hospital as soon as possible.

Inhalation: Remove casualty from exposure ensuring one's own safety whilst doing so. Consult a

doctor.

4.2. Most important symptoms and effects, both acute and delayed

Skin contact: There may be mild irritation at the site of contact.

Eye contact: There may be irritation and redness.

Ingestion: There may be soreness and redness of the mouth and throat. There may be difficulty

swallowing. Nausea and stomach pain may occur. There may be vomiting.

Inhalation: Absorption through the lungs can occur causing symptoms similar to those of ingestion.

Delayed / immediate effects: Immediate effects can be expected after short-term exposure.

4.3. Indication of any immediate medical attention and special treatment needed

Immediate / special treatment: Not applicable.

Section 5: Fire-fighting measures

5.1. Extinguishing media

Extinguishing media: Carbon dioxide, dry chemical powder, foam. Suitable extinguishing media for the

surrounding fire should be used.

5.2. Special hazards arising from the substance or mixture

Exposure hazards: In combustion emits toxic fumes of carbon dioxide / carbon monoxide. Nitrogen oxides

(NOx).

LOVASTATIN

Page: 3

5.3. Advice for fire-fighters

Advice for fire-fighters: Wear self-contained breathing apparatus. Wear protective clothing to prevent contact

with skin and eyes.

Section 6: Accidental release measures

6.1. Personal precautions, protective equipment and emergency procedures

Personal precautions: Refer to section 8 of SDS for personal protection details. Do not create dust. Mark out the

contaminated area with signs and prevent access to unauthorised personnel. If outside

do not approach from downwind.

6.2. Environmental precautions

Environmental precautions: Do not discharge into drains or rivers.

6.3. Methods and material for containment and cleaning up

Clean-up procedures: Transfer to a closable, labelled salvage container for disposal by an appropriate

method.

6.4. Reference to other sections

Reference to other sections: Refer to section 8 of SDS.

Section 7: Handling and storage

7.1. Precautions for safe handling

Handling requirements: Ensure there is sufficient ventilation of the area. Avoid the formation or spread of dust in

the air. Avoid direct contact with the substance. Only use in fume hood.

7.2. Conditions for safe storage, including any incompatibilities

Storage conditions: Store in a cool, well ventilated area. Keep container tightly closed. Store at -20 °C

Suitable packaging: Must only be kept in original packaging.

7.3. Specific end use(s)

Specific end use(s): No data available.

Section 8: Exposure controls/personal protection

8.1. Control parameters

Workplace exposure limits: No data available.

DNEL/PNEC Values

DNEL / PNEC No data available.

8.2. Exposure controls

Engineering measures: Ensure there is sufficient ventilation of the area. **Respiratory protection:** Respiratory protective device with particle filter.

Hand protection: Protective gloves.

Eye protection: Safety glasses. Ensure eye bath is to hand.

LOVASTATIN

Page: 4

Skin protection: Protective clothing.

Section 9: Physical and chemical properties

9.1. Information on basic physical and chemical properties

State: Powder

Colour: Off-white

Solubility in water: Insoluble

Also soluble in: Ethanol. Methanol. Dimethylsulfoxide.

Melting point/range °C: 175 Part.coeff. n-octanol/water: logPow: 4.08

9.2. Other information

Other information: No data available.

Section 10: Stability and reactivity

10.1. Reactivity

Reactivity: Stable under recommended transport or storage conditions.

10.2. Chemical stability

Chemical stability: Stable under normal conditions.

10.3. Possibility of hazardous reactions

Hazardous reactions: Hazardous reactions will not occur under normal transport or storage conditions.

Decomposition may occur on exposure to conditions or materials listed below.

10.4. Conditions to avoid

Conditions to avoid: Heat.

10.5. Incompatible materials

Materials to avoid: Strong oxidising agents. Strong acids.

10.6. Hazardous decomposition products

Haz. decomp. products: In combustion emits toxic fumes of carbon dioxide / carbon monoxide. Nitrogen oxides

(NOx).

Section 11: Toxicological information

11.1. Information on toxicological effects

Toxicity values:

Route	Species	Test	Value	Units
ORAL	MUS	LD50	>1000	mg/kg

LOVASTATIN

Page: 5

Hazardous ingredients:

LOVASTATIN

ORAL	MUS	LD50	>1000	mg/kg
------	-----	------	-------	-------

Relevant hazards for substance:

Hazard	Route	Basis
Acute toxicity (ac. tox. 4)	ING	Hazardous: calculated
Reproductive toxicity		Hazardous: calculated

Symptoms / routes of exposure

Skin contact: There may be mild irritation at the site of contact.

Eye contact: There may be irritation and redness.

Ingestion: There may be soreness and redness of the mouth and throat. There may be difficulty

swallowing. Nausea and stomach pain may occur. There may be vomiting.

Inhalation: Absorption through the lungs can occur causing symptoms similar to those of ingestion.

Delayed / immediate effects: Immediate effects can be expected after short-term exposure.

Other information: Experiments have shown reproductive toxicity effects on laboratory animals

Section 12: Ecological information

12.1. Toxicity

Ecotoxicity values: No data available.

12.2. Persistence and degradability

Persistence and degradability: No data available.

12.3. Bioaccumulative potential

Bioaccumulative potential: No data available.

12.4. Mobility in soil

Mobility: Insoluble in water.

12.5. Results of PBT and vPvB assessment

PBT identification: This product is not identified as a PBT/vPvB substance.

12.6. Other adverse effects

Other adverse effects: No data available.

Section 13: Disposal considerations

13.1. Waste treatment methods

Disposal operations: MATERIAL SHOULD BE DISPOSED OF IN ACCORDANCE WITH LOCAL, STATE AND

FEDERAL REGULATIONS

Disposal of packaging: Dispose of as special waste in compliance with local and national regulations Observe

all federal, state and local environmental regulations.

LOVASTATIN

Page: 6

NB: The user's attention is drawn to the possible existence of regional or national regulations regarding disposal.

Section 14: Transport information

Transport class: This product does not require a classification for transport.

Section 15: Regulatory information

15.1. Safety, health and environmental regulations/legislation specific for the substance or mixture

Specific regulations: Not applicable.

15.2. Chemical Safety Assessment

Chemical safety assessment: A chemical safety assessment has not been carried out for the substance or the mixture

by the supplier.

Section 16: Other information

Other information

Other information: This safety data sheet is prepared in accordance with Commission Regulation (EU) No 453/2010.

> * Data predicted using computational software. The OECD QSAR-Toolbox for grouping chemicals into categories. Developed by LMC bulgaria.

http://echa.europa.eu/support/oecd-qsar-toolbox

~ Data predicted using computational software ACD/ToxSuite v 2.95.1 Copyright 1994-2009 ACD/labs, Copyright 2001-2009 Pharma Algorithms, Inc., Advanced Chemistry Development, Inc (ACD/Labs). http://www.acdlabs.com/products/pc_admet/tox/tox/

Phrases used in s.2 and s.3: H302: Harmful if swallowed.

H361d: Suspected of damaging the unborn child.

Legal disclaimer: The material is intended for research purposes only and should be handled exclusively by those who have been fully trained in safety, laboratory and chemical handling procedures. The above information is believed to be correct to the best of our knowledge. The above information is believed to be correct to the best of our knowledge at the date of its publication, but should not be considered to be all inclusive. It should be used only as a guide for safe handling, storage, transportation and disposal. We cannot guarantee that the hazards detailed in this document are the only hazards that exist for this product. This is not a warranty and Apollo Scientific Ltd shall not be held liable for any damage resulting from handling or from contact with the above product.